Mary-Elizabeth Percival, MD

                            June 19, 2017



Mary-Elizabeth Muchmore Percival, MD, MS

University of Washington

825 Eastlake Ave E

Box 358081 / MS G3200

Seattle, WA  98109-1023


1. Personal Data

Place of Birth: Seattle, WA


2. Education

1996-2000              AB, Biochemical Sciences, magna cum laude, Harvard University, Cambridge, MA

              2002-2007                            MD, Stanford University, Stanford, CA

2014-2016              MS, Epidemiology and Clinical Research, Stanford University, Stanford, CA


3. Post-graduate Training

2007-2008              Intern in Internal Medicine, University of California, San Francisco

2008-2010              Resident in Internal Medicine, University of California, San Francisco

2011-2015              Fellow, Department of Medicine, Divisions of Hematology and Oncology, Stanford University, Stanford, CA


4. Faculty Positions Held

2010-2011              Clinical Instructor of Medicine (Hospital Medicine), University of California, San Francisco

2014-2015              Clinical Instructor of Medicine (Hematology), Stanford University, Stanford, CA

2015-              Assistant Professor of Medicine (Hematology), University of Washington, Seattle, WA

2015-              Assistant Member (Clinical Research Division), Fred Hutchinson Cancer Research Center, Seattle, WA


5. Hospital Positions Held:

2010-2011              Attending Physician, University of California, San Francisco

2014-2015              Attending Physician, Stanford Hospital and Clinics, Stanford, CA

2015-              Attending Physician, University of Washington Medical Center, Seattle, WA


6. Honors

              1996-2000                            Harvard College Scholarship

              2003, 2004-2005              Stanford Medical Scholars Grant

              2004-2005                            Howard Hughes Medical Institute Research Fellow

2005-2006                            Howard Hughes Medical Institute Continuing Scholars Award

2006              Society of General Internal Medicine Annual Meeting, Best Vignette Presentation

2014              American Society of Clinical Oncology Young Investigator Award

2014              American Society of Hematology Senior Research Training Award for Fellows (award declined)

2014-2015                            KL2 Mentored Career Development Award


7. Board Certification

              2010                                          Diplomate, American Board of Internal Medicine

              2014                                          Diplomate, American Board of Internal Medicine, Hematology

2015              Diplomate, American Board of Internal Medicine, Medical Oncology


8. Licensure

              2009-2016                            California State Medical License (A106581)

              2015-                                          Washington State Medical License (60591746)


9. Professional Organizations

              2011 -              2015                            Associate Member, American Society of Hematology (1039530)

              2015 -                                          Member, American Society of Hematology

2011-2014              Member in training, American Society of Clinical Oncology (224579)

              2014 -                                          Member, American Society of Clinical Oncology


10. Teaching Responsibilities:

2015-              Clinical teaching, inpatient leukemia service, University of Washington Medical Center

2016-              Clinical teaching, outpatient leukemia clinic, Seattle Cancer Care Alliance

2016-              Small group leader for medical student hematology course, University of Washington


11. Special National Responsibilities:

2012-2014                            Member, American Society of Hematology Trainee Council

              2013-2014                            Chair, American Society of Hematology Trainee Council

2013-2014              Member, American Society of Hematology Committee on Training

2013              Participant, ASCO/AACR Methods in Clinical Cancer Research Workshop (Vail, CO)

2015-2020              Member, ACGME Standing Panel for Accreditation Appeals in Internal Medicine – Hematology/Medical Oncology

2015              Member, ASH Teaching Cases Subcommittee (of Committee on Educational Affairs)


12. Special Local Responsibilities:

2015-              Member, AML Clinical Pathway Development (Seattle Cancer Care Alliance)

2016-               Member, Scientific Review Committee A (Fred Hutchinson Cancer Research Center)


13. Research funding:


              2016-2019                            Sponsor: Cancer Consortium Support Grant

Title: A pilot study of early allogeneic hematopoietic cell transplantation for relapsed/refractory acute myeloid leukemia

                                                        Amount: $80,000

                                                        Role: PI



2014-2015              Sponsor: American Society of Clinical Oncology, Young Investigator Award

Title: Clinical and pharmacodynamic evaluation of MEK inhibition in combination with conventional chemotherapy in RAS-mutated AML

Amount: $50,000

Role: PI


              2014-2015                            Sponsor: Stanford CTSA to Spectrum NIH KL2 TR 001083

Title: Improvements in early mortality in acute myeloid leukemia patients undergoing induction chemotherapy: implications for future comparative effectiveness research

Amount: 75% salary and tuition for Master’s degree for 2 years


14. Publications

A. Journal publications

        1. Muchmore ME, Moy GW, Swanson WJ, Vacquier VD. “Direct sequencing of genomic DNA for characterization of a satellite DNA in five species of Eastern Pacific abalone.” Molecular Marine Biology and Biotechnology 7.1 (1998): 1-6. PMID: 9597772
        2. Chobotova K, Muchmore ME, Carver J, Yoo HJ, Manek S, Gullick WJ, Barlow DH, Mardon HJ. “The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha.” Journal of Clinical Endocrinology and Metabolism. 87.12 (2002 Dec): 5769-77. PMID 12466384
        3. Yee SW, Mefford JA, Singh N, Percival ME, Stecula A, Yang K, Witte JS, Takahashi A, Kubo M, Matsuda K, Giacomini KM, Andreadis C. “Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.” J Hum Genet. 2013 Jun;58(6):353-61. PMID 23677058
        4. Percival ME and Colevas AD. “Biased view of the role of site-specific therapy in carcinoma of unknown primary.” J Clin Oncol. 2013 Jul 1;31(19):2512-3. PMID 23733770
        5. Percival ME, Hoppe RT, and Advani RH. “How an expert approaches it: bulky mediastinal classical Hodgkin lymphoma in young women.” Oncology. 2014 Mar;28(3):253-6, 258-60, C3. PMID: 24855735
        6. Percival ME and Medeiros BC. “Chemotherapy dose in obese AML patients: To cap or not to cap?” Leuk Res 2015 Jan;39(1):30-2. PMID: 25499234
        7. Percival ME, Tao L, Medeiros BC, Clarke CA. “Improvements in the early death rate in 9,380 acute myeloid leukemia patients following initial therapy: a SEER database analysis.” Cancer 2015 Jun 15;121(12):2004-12. PMID: 25739348
        8. Percival ME, Medeiros BC, Tian L, Robeson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Weng WK, Negrin RS, Lowsky R. “Allogeneic hematopoietic cell transplant for normal karyotype acute myeloid leukemia: Indirect evidence of selection for adverse molecular profile.” Bone Marrow Transplant 2015 Jul;50(7):1004-6. PMID: 25893457
        9. Narayan R, Garcia JS, Percival ME, Berube C, Coutre S, Gotlib J, Greenberg P, Liedtke M, Hewitt R, Regan K, Williamson C, Doykan C, Cardone MH, McMillan A, Medeiros BC. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.Leuk Lymphoma 2016;57(3):609-15. PMID: 26374199
        10. Percival ME, Lai C, Estey E, Hourigan CS. “Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.” Blood Rev 2017 Feb 2. PMID 28190619
        11. Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival ME, Estey EH, Stirewalt DL, Walter RB. “Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.” Leukemia 2017 May 30. PMID 28555084


B. Book chapters

  1. Percival ME and Gonzales R. “Asthma and COPD.” In: Chiovaro J, Durand K, Lai C, eds. UCSF Outpatient Medicine Pocket Preceptor. University of California San Francisco. November 2009.


C. Published Books, Videos, Software, etc.: none


D. Other publications

  1. Percival ME and Walter RB. “Emerging treatments in acute myeloid leukemia (AML).” September 2016. Cyberounds online continuing medical education website:


E. Manuscripts submitted

  1. Percival ME and Estey EH. “Chapter 10: Cure of APL Without Chemotherapy.” Solicited book chapter, submitted October 2016.
  2. Buckley SA, Percival ME, et al. “A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.” Submitted May 2017.
  3. Percival ME and Estey EH. “Emerging treatments in AML: current standards and unmet challenges.” Submitted May 2017.


F. Abstracts

  1. Muchmore ME, Burge MJ, Shizuru JA. “Durable engraftment of purified allogeneic hematopoietic stem cells following non-myeloablative conditioning.” Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 2204.
  2. Muchmore ME and Helgerson P. “Be Still My Heart! A Shocking Diagnosis In a 54-Year-Old Man With Non-Ischemic Cardiac Arrest.” Invited oral presentation. Society of General Internal Medicine Annual Meeting. Los Angeles, CA. April 2006.
  3. Percival ME et al. “Long-term outcomes in patients with acute myelogenous leukemia following allogeneic stem cell transplantation for relapse after initial autologous bone marrow transplant.” Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2299.
  4. Percival ME et al. “Improvements in the early death rate in younger acute myeloid leukemia patients following initial therapy: a SEER database analysis.” Blood (ASH Annual Meeting Abstracts), Nov 2014; 124: 3696.


Complete List of Published Work in MyBibliography